AI Models for Non-invasive Glycaemic Event Detection Using ECG in Type 1 Diabetics

Sponsor
University Hospitals Coventry and Warwickshire NHS Trust (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05461144
Collaborator
University of Warwick (Other)
30
55

Study Details

Study Description

Brief Summary

This observational study aims to recruit up to thirty T1DM patients from a diabetic outpatient clinic at the University Hospital Coventry and Warwickshire for a two-phase study. The first phase involves attending an inpatient protocol for up to thirty-six hours in a calorimetry room at the Human Metabolism Research Unit under controlled conditions, followed by a phase of free-living, for up to three days, in which participants will go about their normal daily activities without restriction. Throughout the study, the participants will wear commercially available wearable sensors to measure and record physiological signals (e.g., electrocardiogram and continuous glucose monitor). Data collected will be used to develop and validate an AI model using state-of-the-art deep-learning methods for the purpose of non-invasive glycaemic event detection.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The study volunteers will be asked to an attend an 'inpatient' facility for up to 36 hrs dedicated to advanced metabolic measurement (HMRU). They will be asked to consume prepared meals of varying macronutrient content as part of a balanced diet, and performed prescribed physical activity. During this time the volunteers will be measured by instrumentation which will investigate the chemical concentration in respired gases (e.g. whole-body calorimeters, metabolic carts); bloods, saliva and urine samples will be taken. If the participant then wishes, we will ask them to continue to wear the wearable devices in a home setting for a maximum one week.

    The data derived from this study will allow new tools and mathematical models to be developed that can be used to analyse and simulate patient metabolic response. It is envisaged this study will give further evidence to support future research into glucose utilisation in diseased metabolic populations.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    30 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Development and Validation of Artificial Intelligence Models for Non-invasive Glycaemic Event Detection Using ECG in Type 1 Diabetics
    Anticipated Study Start Date :
    Sep 30, 2022
    Anticipated Primary Completion Date :
    May 1, 2026
    Anticipated Study Completion Date :
    May 1, 2027

    Arms and Interventions

    Arm Intervention/Treatment
    Type1diabetes patients

    Males and females diagnosed with T1D, aged over 18 years old who are currently under the care of the Warwickshire Institute for the Study of Diabetes, Endocrinolgy and Metabolism (WISDEM) at the University Hospitals Coventry and Warwickshire.

    Outcome Measures

    Primary Outcome Measures

    1. Interstitial Glucose [For the duration of the study, up to 5 days]

      As measured by a continuous glucose monitor [NOTE] Observational study thus a key measurement not a true outcome measure.

    Secondary Outcome Measures

    1. ECG -Interval across different fiducial points [For the duration of the study, up to 5 days]

      As measured by an ambulatory ECG device [NOTE] Observational study thus a key measurement not a true outcome measure. The interval across different fiducial points (P.Q.R,S,T) is one of the features that are useful to quantify the difference in ECG signals for different glycaemic events.

    2. ECG - Slope across different fiducial points [For the duration of the study, up to 5 days]

      As measured by an ambulatory ECG device [NOTE] Observational study thus a key measurement not a true outcome measure. The Slope across different fiducial points (P.Q.R,S,T) is one of the features that are useful to quantify the difference in ECG signals for different glycaemic events.

    3. ECG - Indices of Heart Rate Variability [For the duration of the study, up to 5 days]

      As measured by an ambulatory ECG device [NOTE] Observational study thus a key measurement not a true outcome measure. Heart rate variability (HRV) is the fluctuation in the time intervals between adjacent heartbeats. There are several indices that are useful to quantify the difference in ECG signals for different glycaemic events such as Ultra Low Frequency (ULF) (≤0.003 Hz), Very Low Frequency (VLF) (0.0033-0.04 Hz), Low Frequency (LF) (0.04-0.15 Hz) and High Frequency (HF) (0.15-0.4 Hz)

    4. Blood Pressure (Systolic and Diastolic) [For the duration of the study, up to 5 days]

      As measured by an ambulatory blood pressure device [NOTE] Observational study thus a key measurement not a true outcome measure.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:

    The study will be open to all individuals living independently, over 18 years without acute illness or ongoing clinical investigation, or volunteers with a stable medical condition may be included. Volunteers with an ongoing medical condition will only be included after detailed consultation with our clinical and dietetics members of the team; however, it is imperative that volunteers are able to provide written informed consent.

    Exclusion Criteria:

    Whilst the study employs a deliberately open inclusion criterion, the following exclusion measures will be employed:

    • Children (under 18 yrs)

    • Any adult who lacks decisional capacity

    • Claustrophobia, isolophobia, recent abnormal exercise, radiation exposure within the preceding 24 hours of entering the whole-body calorimeter and feeling unwell in any way.

    • Needle phobia

    • Any medical/endocrine problem that could affect energy expenditure (e.g. thyroid problems, Cushing's syndrome)

    • Chronic inflammatory disorders like rheumatoid arthritis, or long term use of steroids or other immunomodulators like cyclosporine, azathioprine.

    • Beta blockers

    • Currently actively losing weight

    • Depression or any psychiatric illness

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • University Hospitals Coventry and Warwickshire NHS Trust
    • University of Warwick

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    University Hospitals Coventry and Warwickshire NHS Trust
    ClinicalTrials.gov Identifier:
    NCT05461144
    Other Study ID Numbers:
    • JH206817a
    First Posted:
    Jul 15, 2022
    Last Update Posted:
    Jul 15, 2022
    Last Verified:
    Jul 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by University Hospitals Coventry and Warwickshire NHS Trust
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 15, 2022